<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aprea Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/aprea-therapeutics-inc</link>
<description>Latest news and press releases for Aprea Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aprea-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835473978dffbe2df0e3500.webp</url>
<title>Aprea Therapeutics, Inc.</title>
<link>https://6ix.com/company/aprea-therapeutics-inc</link>
</image>
<item>
<title>Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-closing-of-oversubscribed-dollar30-million-private-placement-1</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-closing-of-oversubscribed-dollar30-million-private-placement-1</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suited DOYLESTOWN,</description>
</item>
<item>
<title>Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-oversubscribed-dollar30-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-oversubscribed-dollar30-million-private-placement</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors</description>
</item>
<item>
<title>Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer</description>
</item>
<item>
<title>Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-additional-positive-clinical-activity-for-wee1-inhibitor-apr-1051-including-second-partial-response-in-ongoing-acesot-1051-trial</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-additional-positive-clinical-activity-for-wee1-inhibitor-apr-1051-including-second-partial-response-in-ongoing-acesot-1051-trial</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose levelPatient experienced only Grade 1 adverse events Represents</description>
</item>
<item>
<title>Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-present-oppenheimer-36th-130000251</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-present-oppenheimer-36th-130000251</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced that Oren Gilad, Ph.D., President and CEO, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, to take place February 25-26, 2026, virtually. Presentation</description>
</item>
<item>
<title>Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-strengthens-global-patent-133000861</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-strengthens-global-patent-133000861</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept demonstrated and multiple 2026 data readouts anticipated Broad intellectual property protection and ongoing clinical progress position Aprea for long-term value creation DOYLESTOWN, Pa., Feb. 12, 2026 (GLOBE NEW</description>
</item>
<item>
<title>Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-appoints-industry-veteran-133000219</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-appoints-industry-veteran-133000219</guid>
<pubDate>Wed, 04 Feb 2026 13:30:00 GMT</pubDate>
<description>Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy j</description>
</item>
<item>
<title>Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-early-clinical-132700895</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-early-clinical-132700895</guid>
<pubDate>Thu, 29 Jan 2026 13:27:00 GMT</pubDate>
<description>Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response (uPR) that was observed in the first scan has been achieved at the 150 mg dose, with 220 mg cohort currently enrolling in the ACESOT-1051Potential dose-response trend observed with increasing single-agent activity across the 70 mg, 100 mg, and 150 mg cohortsData provide early clinical proof-of-concept for single-agent APR-1051 in patients wit</description>
</item>
<item>
<title>Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-5-6-132500419</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-5-6-132500419</guid>
<pubDate>Thu, 29 Jan 2026 13:25:00 GMT</pubDate>
<description>DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certain insiders of the Company to sell an aggregate of 6,288,857 shar</description>
</item>
<item>
<title>Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-ceo-issues-letter-133000412</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-ceo-issues-letter-133000412</guid>
<pubDate>Thu, 18 Dec 2025 13:30:00 GMT</pubDate>
<description>DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses in cancer cells while minimizing damage to healthy cells, today issued the following letter to shareholders from Chief Executive Officer, Oren Gilad. The letter highlights the Company’s ongoing clinical progress, operational execution, and plans for 2026. Dear Shareholders -- As 2</description>
</item>
<item>
<title>Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-3-1-133000088</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-3-1-133000088</guid>
<pubDate>Tue, 09 Dec 2025 13:30:00 GMT</pubDate>
<description>Financing from new and existing healthcare focused investors The proceeds are expected to extend the Company’s cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that period DOYLESTOWN, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to h</description>
</item>
<item>
<title>Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-reports-third-quarter-133000489</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-reports-third-quarter-133000489</guid>
<pubDate>Wed, 12 Nov 2025 13:30:00 GMT</pubDate>
<description>APR-1051 (WEE1 kinase inhibitor): In ongoing Phase 1 ACESOT-1051dose-escalation trial, 3 out of 4 patients at Dose Level 6 (100 mg once daily) achieved stable disease, per RECIST v1.1, in heavily pretreated gastrointestinal and gynecologic malignanciesATRN-119 (ATR kinase Inhibitor): RP2D of 1,100 mg once daily identified in ABOYA-119 dose-escalation studyPosters on APR-1051 and ATRN-119 featured at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics DOYLESTOWN,</description>
</item>
<item>
<title>Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-provides-clinical-acesot-123000702</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-provides-clinical-acesot-123000702</guid>
<pubDate>Fri, 24 Oct 2025 12:30:00 GMT</pubDate>
<description>3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors harboring mutations relevant to WEE1 kinase inhibition (FBXW7, CCNE1, KRAS G12V and TP53)Dose escalation continues, with patients now enrolling in 150 mg cohortPreliminary results from ACESOT-1051 trial through September 17, 2025 to be featured in poster presentation today at the A</description>
</item>
<item>
<title>Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-establishes-recommended-phase-120000654</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-establishes-recommended-phase-120000654</guid>
<pubDate>Wed, 15 Oct 2025 12:00:00 GMT</pubDate>
<description>ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 monotherapy enrollment paused with strategic focus on high-value combinationCompany is prioritizing its lead program, WEE1 kinase inhibitor APR-1051 DOYLESTOWN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer ce</description>
</item>
<item>
<title>Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-presentations-eortc-120000098</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-presentations-eortc-120000098</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that two abstracts on its clinical programs, APR-1051 amd ATRN-119, have been accepted for poster presentation at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therap</description>
</item>
<item>
<title>Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-present-h-c-123000907</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-present-h-c-123000907</guid>
<pubDate>Thu, 28 Aug 2025 12:30:00 GMT</pubDate>
<description>DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York. Presentation Details Date/ time: Tuesday, September 9</description>
</item>
<item>
<title>Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-reports-second-quarter-120000228</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-reports-second-quarter-120000228</guid>
<pubDate>Tue, 12 Aug 2025 12:00:00 GMT</pubDate>
<description>Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051 $16.5 million in cash and cash equivalents as of June 30, 2025 DOYLESTOWN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell</description>
</item>
<item>
<title>Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-reports-anti-proliferative-results-130000497</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-reports-anti-proliferative-results-130000497</guid>
<pubDate>Wed, 25 Jun 2025 13:00:00 GMT</pubDate>
<description>Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051 DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer</description>
</item>
<item>
<title>Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-reports-first-quarter-120000004</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-reports-first-quarter-120000004</guid>
<pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
<description>ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7%, 14% and 21% ACESOT-1051, the Phase 1 trial of WEE1 inhibitor APR-1051, continues to advance, with patients now being dosed at 100 mg once daily $19.3 million in cash and cash equivalen</description>
</item>
<item>
<title>Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial</title>
<link>https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-dosing-patient-123000322</link>
<guid isPermaLink="true">https://6ix.com/company/aprea-therapeutics-inc/news/aprea-therapeutics-announces-dosing-patient-123000322</guid>
<pubDate>Mon, 31 Mar 2025 12:30:00 GMT</pubDate>
<description>ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that a patient with HPV+ head an</description>
</item>
</channel>
</rss>